Archive | August, 2021

Hot Longevity Mandate: Chinese Pharmaceutical Company

17 Aug

The firm is a biopharmaceutical company focused on researching, developing, and commercializing innovative immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and worldwide. Established in 2015, the firm has assembled a world-class management team with extensive experience in innovative drug development, clinical research, and commercialization. The company has built an oncology-focused pipeline of 15 drug candidates with a strategic emphasis on immuno-oncology combination therapies. The firm has received three NDA approvals, including two in mainland China and one in Taiwan, and multiple late-stage candidates are in pivotal trials or registrational stages. The firm’s vision is to become globally recognized as a world-renowned biopharmaceutical company by bringing innovative oncology therapies to cancer patients worldwide. The company is currently seeking in-licensing, out-licensing and partnership opportunities globally.

The firm is particularly interested in first-in-class, truly innovative oncology assets from pre-clinical to market except for CAR-T therapy and gene therapy. The firm is interested in opportunities for both greater China as well as global market.

The firm’s team is flexible and is open to working with all different kinds of management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

Hot AI Mandate: US-based Family Office Invests in Medical Devices, Diagnostics & Digital Health

17 Aug

Founded in 2011 and based is Dallas, Taxas, the firm is focused on healthcare companies and makes seed, venture, and growth stage investments. The firm typically provides seed and Series A equity financing in the range of $100K to $1M per portfolio company. The firm generally acts as the lead investor and is open to investing in syndicates. The firm primarily invests in companies that are based in Texas but is open to opportunities across North America. The firm is actively seeking new investment opportunities.

The firm is currently seeking to invest in medical devices, diagnostics, digital health, and software. The firm is also interested in reformulated and repurposed drugs that have mitigated risk. For medical devices, the firm is opportunistic in terms of subsectors. Ideally, the product has a prototype and 510(k) regulatory pathway. The firm is open to investing in any indication, including orphan diseases; the dental field is of interest.

The firm seeks a strong and experienced management team. The firm may take a board seat where appropriate.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

Hot AI Mandate: Boston-based VC Targets Healthcare Technology & Services

17 Aug

A healthcare venture capital investment firm was founded in 2001 and is based in Boston, Massachusetts. The firm currently manages over $450 million, including their recently announced $255 million second healthcare IT and services focused venture fund in July 2019. The firm generally makes investments in early stage companies targeting healthcare technology and services. The investment size will vary, depending on the opportunity. The firm typically invests in companies based in the United States though is open to companies based on a global level.

In the healthcare technology sector, the firm is actively seeking new investments in healthcare software and tech-enabled services sectors with a specific focus on payment reform, patients as consumers, healthcare analytics, healthcare infrastructure, and novel service delivery models. The firm has a specific interest in transformational technologies and services that enable value-based healthcare. The firm currently is not focused on therapeutics or traditional medical device investment opportunities, though may consider medical devices with a software/data component, such as sensors, that have either already obtained FDA clearance or are not subject to FDA regulation. The firm is indication agnostic and invests in pre-revenue to growth stage products.

The firm seeks to invest in privately held companies with a strong and experience management team. The group prefers to invest in companies with cutting-edge technologies and large market potential.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

Hot AI Mandate: Investment Firm Expanding into Life Sciences is Looking for New Opportunities

17 Aug

Based in Oklahoma City, an investment firm previously in the energy and oil space, and in the last year has expanded their interests to begin investing in the life science space as well. The firm is looking for new investment opportunities in the therapeutics, medical devices, diagnostics, and digital health sectors. The firm invests in Seed, Series A and B and is willing to both lead or participate in the investments. The firm is opportunistic in terms of sub-sectors and indications including all phases of development for therapeutics. Since starting to invest in the biotech space last fall, the firm currently has made 5 investments. The typical check size ranges from $500K up to $6M depending on the company and syndicate. The firm focuses on companies located in the United States.

The firm is looking for new investment opportunities in the therapeutics, medical devices, diagnostics, and digital health sectors. The firm is opportunistic in terms of sub-sectors and indications, including 510K and PMA classes of medical devices, as well as all phases of development for therapeutics including pre-clinical companies. The firm is also open to looking at pre-prototype companies on a case by case basis

The firm looks for a management team with a proven track record and strong sector knowledge and experience. The firm looks for companies who have done regulatory submission and successful exits as well. The firm is open to both leading or coinvesting in the investment and seeks board seat representation when leading an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

Automating Medical Visits Using Artificial Intelligence (AI) and Augmented Reality (AR) – Interview with James Bates, MS, CEO of AdviNOW Medical

16 Aug

By Erika Wu, Business Development Representative, LSN

What if we could automate and improve medical visits by reducing in-person patient contact, administrative burdens and operation costs? Hear what CEO James Bates and his team at AdviNOW Medical are doing to utilize AR and AI to expand healthcare access to anywhere you are. RESI AI returns September 16-17 with dynamic panels, as well as opportunities to pitch to a live panel of AI investors. Get involved and tell your story at  Innovator’s Pitch Challenge! Applications are due by Friday, August 20, so submit yours today!

September Partnering Opens Soon

12 Aug

By Karen Deyo, Director of Investor Research, Israel BD, LSN

Life Science Nation (LSN)’s mission is to connect products, services, and capital to advance deals that save lives. There are many opportunities to achieve this in the early-stage life science ecosystem, but few more powerful than well-matched partnering, which is why LSN’s match-based partnering platform can be a game-changer for fundraising entrepreneurs.

Learn more about virtual partnering at LSN events at one of our free fundraising bootcamps coming up on Wednesday, August 18 at 2 PM EDT. Register here for the complimentary webinar. These events give an overview of LSN’s partnering system, what sets it apart, and why a comprehensive strategy is essential to succeed in booking meetings with qualified investors.

Check out some of our resources below to help you succeed in your partnering, and sign up for our one-day prep course ahead of RESI Partnering Week, September 13-17 to get started!

Pitch Deadline Approaching

12 Aug

By Rory McCann, Marketing Manager & Conference Producer, LSN

The application deadline to pitch at RESI Partnering Week, September 13-17 is around the corner. Submit your application to pitch directly to a panel of relevant investors by August 20. Applications are accepted on a rolling basis.

The Innovator’s Pitch Challenge (IPC) provides an opportunity for life science startups to pitch directly to a panel of investors during a live Q&A session, providing valuable insights and feedback. Participants build connections between fundraising founders and potential investors on the panel and in the audience.

Participating companies receive:

  1. A dedicated page showcasing a pre-recorded pitch video, pitch deck, and executive summary
  2. A spot in the live pitch session and Q&A with investors actively seeking assets in their sector
  3. Global visibility to partners that are a fit for their stage of development and product
  4. Increased global footprint, opportunities to engage with global partners, and valuable, insightful feedback

Hear from recent IPC winners, see what investors have to say, and sign up today to pitch at RESI Partnering Week!

See What Investors Are Saying about The Innovator’s Pitch Challenge

“It was a very economical use of time; the investors got to ask their important questions and the Innovators got a good idea of the most pressing questions from the investors point of view.”
William Kuziel, MedPro Investors
 
“The Pitch Sessions are a great opportunity to connect with startup CEOs and learn more about their work…It really has been an effective and efficient way to make connections, create deal flow and help startups raise money for their upcoming raises.”
Mayank Taneja, OSF Healthcare
 
“I look forward to LSN’s events because they provide an opportunity for our venture capital firm to find promising companies with exceptional technologies. The organization and technology platform make it very easy to hear numerous pitches from founders.”
Nat Brinn, VC23
 
“The Pitch Sessions were a great opportunity to engage with the CEO/Founders of very innovative Life Science startups. Despite the COVID-related transition from in-person to virtual meetings, the RESI team did an outstanding job organizing these sessions, ensuring that the live Q&A was very productive, and facilitating follow-up with these exciting companies.”
Gary Gershony, Life Science Angels / BayMed Venture Partners
← Older Entries
Newer Entries →